tetracycline

This product is a broad-spectrum antibacterial agent with bactericidal effect at high concentrations. In addition to common Gram-positive bacteria, Gram-negative bacteria and anaerobic bacteria, most Rickettsia, Mycoplasma, Chlamydia, atypical mycobacteria and spirochetes are also sensitive to this product. This product is more effective against Gram-positive bacteria than Gram-negative bacteria, but Enterococcus is resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, etc. are sensitive to this product. This product has certain antibacterial activity against Neisseria gonorrhoeae, but penicillin-resistant gonococci are also resistant to tetracycline. This product has good antibacterial effect on Gram-negative bacteria such as Vibrio, Yersinia pestis, Brucella, Campylobacter, Yersinia, etc., has no antibacterial activity against Pseudomonas aeruginosa, and has certain antibacterial effect on some anaerobic bacteria, but it is far less than...

The main component of this product is tetracycline. Its chemical name is 6-methyl-4-(dimethylamino)-3,6,10,12,12α-pentahydroxy-1,11-dioxo-1,4,4α,5,5α,6,11,12α-octahydro-2-naphthacenecarboxamide. Molecular formula: C22H24N2O8. Molecular weight: 444.44.

1. This product is used as the first choice or optional drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides for the treatment of brucellosis and plague. 2. Due to the serious resistance of common pathogens to tetracyclines, this drug is only indicated when the pathogen is sensitive to this drug. Since hemolytic streptococci are mostly resistant to this drug, it is not suitable for infections caused by this type of bacteria.

Oral administration, the usual dosage for adults is 0.25-0.5g at a time, once every 6 hours. The usual dosage for children over 8 years old is 25-50mg/kg each time, once every 6 hours. The course of treatment is generally 7-14 days, while mycoplasma pneumonia and brucellosis require about 3 weeks.

[Adverse Reactions] 1 Digestive system: Gastrointestinal symptoms such as nausea, vomiting, upper abdominal discomfort, abdominal distension, diarrhea, and occasionally pancreatitis. There are occasional reports of esophagitis and esophageal ulcers, which mostly occur in patients who go to bed immediately after taking the medicine. 2 Hepatotoxicity: Usually fatty liver degeneration, which is prone to occur in pregnant women and patients with existing renal damage, and can also occur in patients without the above conditions. Pancreatitis caused by this product can also occur simultaneously with hepatotoxicity, and the patient does not have primary liver disease. 3 Allergic reactions: Mostly maculopapular rash and erythema, in addition to urticaria, angioedema, allergic purpura, pericarditis and worsening of skin lesions of systemic lupus erythematosus, epidermal exfoliative dermatitis is not common. Occasionally, anaphylactic shock and asthma occur. Some patients using this product may have photosensitivity when exposed to the sun.

It is contraindicated for patients who are allergic to tetracyclines.

1 When used together with antacids such as sodium bicarbonate, the absorption of this product may be reduced and its activity may be reduced due to the increased pH value in the stomach. Therefore, antacids should not be taken within 1 to 3 hours after taking this product. 2 Drugs containing metal ions such as calcium, magnesium, and iron may form insoluble complexes with this product, reducing the absorption of this product after oral administration. 3 When used in combination with the general anesthetic methoxyflurane, its nephrotoxicity may be enhanced. 4 When used in combination with strong diuretics such as furosemide and other drugs, renal damage may be aggravated. 5 When used in combination with other hepatotoxic drugs (such as anti-tumor chemotherapy drugs), liver damage may be aggravated. 6 The lipid-lowering drugs colestyramine or colestipol may affect the absorption of this product and must be taken several hours apart. 7 This product may reduce the effectiveness of contraceptives and increase the possibility of extramenstrual bleeding. 8

Keep away from light, sealed and stored in a dry place.

API

24 months

Hebei BRIC Pharmaceutical Co., Ltd.

• Founded in:

  2004-07-23

• Address:

  No. 88, Taibai Road, Linmingguan Town, Yongnian District, Handan City, Hebei Province

• Tax NO.:

  911304297651679024

• Registered Funds:

  210 million yuan

• Email:

  Log in to view